bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-3420

Order Name:
SigNatera subsequent test, Blood **

 
Useful For:
Detect circulating tumor DNA (ctDNA) for recurrence monitoring for patients previously diagnosed with cancer and tested for the innitial test.
 
Methodology:
Detect ctDNA 
 
 
 
Test Code:
090-71-3420

Order Name:
SigNatera subsequent test, Blood **

 
Patient Preparation:
Previously sent SigNatera initial test, Tissue (FFPE) + Blood **
 
Collection Specimen Or Container:
Blood (SigNatera Kit) - Two 10mL Streck tubes 

Document Required
Filled Requisition Form & Sign Consent 
 
Specimen Testing Type:
Whole blood 10mL Streck x 2 tubes 
 
Sub Mission Container:
SigNatera blood collection Kit
 
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood Ambient temperature 7 days *
* Sent to USA
 
 
 
Test Code:
090-71-3420

Order Name:
SigNatera subsequent test, Blood **

 
Method detail:
Detect ctDNA 
 
Schedule:
N/A **Sent out to Natera, Inc., USA
 
 
Turnaround Time:
Received specimen to reported within 5 weeks
 
Performing Location:
Natera, Inc.
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-3420

Order Name:
SigNatera subsequent test, Blood **

 
 
Clinical Information:
“Signatera Test” means Natera’s individual-specific screening test for detecting and monitoring circulating tumor DNA in the plasma of patients previously diagnosed with cancer. Individual-specific mutation signatures are identified by upfront FFPE tissue and matched-normal whole exome sequencing.

Signatera Setup consists of whole exome sequencing of tissue and matched-normal in order to determine the individual-specific mutation signature, to be measured with the Initial Plasma Test and monitored with Subsequent Plasma Tests.
 
Clinical Reference:
www.natera.com/oncology/signatera-clinicians (Retrieved: 22 Jul 2020)